D
11.34
-0.10 (-0.87%)
| Previous Close | 11.44 |
| Open | 11.40 |
| Volume | 113,253 |
| Avg. Volume (3M) | 378,650 |
| Market Cap | 362,582,912 |
| Price / Earnings (Forward) | 106.38 |
| Price / Sales | 13.95 |
| Price / Book | 46.38 |
| 52 Weeks Range | |
| Earnings Date | 24 Mar 2025 - 28 Mar 2025 |
| Operating Margin (TTM) | -50.37% |
| Diluted EPS (TTM) | -1.17 |
| Quarterly Revenue Growth (YOY) | 1,468.90% |
| Total Debt/Equity (MRQ) | 27.91% |
| Current Ratio (MRQ) | 2.56 |
| Operating Cash Flow (TTM) | -31.37 M |
| Levered Free Cash Flow (TTM) | -16.64 M |
| Return on Assets (TTM) | -81.99% |
| Return on Equity (TTM) | -478.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Delcath Systems, Inc. | Bearish | Bullish |
AIStockmoo Score
0.2
| Analyst Consensus | 1.0 |
| Insider Activity | 1.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.20 |
|
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 2.71% |
| % Held by Institutions | 38.13% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (HC Wainwright & Co., 94.00%) | Buy |
| Median | 21.50 (89.59%) | |
| Low | 21.00 (Canaccord Genuity, 85.19%) | Buy |
| Average | 21.50 (89.59%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 10.62 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 11 Nov 2024 | 22.00 (94.00%) | Buy | 9.96 |
| 18 Oct 2024 | 22.00 (94.00%) | Buy | 11.28 | |
| Canaccord Genuity | 18 Oct 2024 | 21.00 (85.19%) | Buy | 11.28 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AHARON GIL | 11.34 | - | 250,000 | 2,835,000 |
| ROSALIND ADVISORS, INC. | 11.34 | - | 250,000 | 2,835,000 |
| SALAMON STEVEN A J | 11.34 | - | 250,000 | 2,835,000 |
| Aggregate Net Quantity | 750,000 | |||
| Aggregate Net Value ($) | 8,505,000 | |||
| Aggregate Avg. Buy ($) | 11.34 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ROSALIND ADVISORS, INC. | Director | 24 Dec 2024 | Acquired (+) | 250,000 | 11.34 | 2,835,000 |
| AHARON GIL | Director | 24 Dec 2024 | Acquired (+) | 250,000 | 11.34 | 2,835,000 |
| SALAMON STEVEN A J | Director | 24 Dec 2024 | Acquired (+) | 250,000 | 11.34 | 2,835,000 |
| Date | Type | Details |
|---|---|---|
| 30 Dec 2024 | Announcement | Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises |
| 02 Dec 2024 | Announcement | Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer |
| 08 Nov 2024 | Announcement | Delcath Systems Reports Third Quarter 2024 Results and Business Highlights |
| 01 Nov 2024 | Announcement | Delcath Systems to Participate in Upcoming Investor Conferences |
| 25 Oct 2024 | Announcement | Delcath Systems to Host Third Quarter 2024 Earnings Call |
| 17 Oct 2024 | Announcement | Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |